Bavarian Nordic shares fall as Q1 revenue misses forecasts

Bavarian Nordic’s Q1 revenue came in at DKK 1.06 billion, below the DKK 1.13 billion consensus, and EBITDA missed sharply at DKK 165 million versus DKK 277 million expected. Public Preparedness revenue was particularly weak at DKK 294 million versus DKK 384 million expected, though Travel Health beat at DKK 721 million. The company raised full-year 2026 revenue guidance to DKK 5.5 billion-DKK 5.7 billion and lifted its EBITDA margin target to about 28%, partially offsetting the quarterly miss.

Analysis

The key signal is not the headline miss; it is the widening gap between revenue quality and reported profitability. A higher mix of preparedness work should eventually support margins, but the near-term P&L is getting pulled down by production cost inflation and an unfavorable mix shift away from the highest-margin vaccine sales. That creates a classic sequencing problem: guidance can look stronger while the next 1-2 quarters still print choppy EBITDA, especially if inventory build or delivery timing stays lumpy.

The market is likely underestimating how much of the upgraded outlook is already monetized in the stock. When management raises full-year revenue and margin targets after a soft quarter, the incremental upside usually comes from order visibility rather than near-term execution, which means the rerating is more vulnerable to any delay in Public Preparedness fulfillment. The biggest second-order risk is that customers and governments, seeing a more normalized mpox demand environment, may pressure pricing or stretch procurement timing, reducing the margin benefit implied by the new guidance.

Contrarian take: this is not a clean bullish reset; it is a de-risking of revenue with a less attractive earnings bridge. The “good news” in guidance may actually cap upside because the market will now need proof that the higher backlog converts into cash without further gross margin slippage. If that conversion disappoints, the stock can re-rate lower even without another revenue miss, since the investment case is increasingly dependent on sustaining the elevated margin target rather than just top-line growth.

Key Decisions for Investors

• Short-term: avoid chasing the rebound; wait 2-4 weeks for post-earnings revision flow to settle before adding long exposure to BAVA. Risk/reward is poor if the stock already discounts the raised guidance, because downside can resume on any margin reset.
• If already long BAVA, hedge via put spread into the next catalyst window (next trading update or contract disclosure). Structure idea: 1-2 month put spreads to protect against a further 8-12% drawdown if investors refocus on EBITDA quality rather than revenue guidance.
• Pair trade: long a higher-quality healthcare platform with recurring demand visibility vs. short BAVA as a “guidance lift, execution lag” expression. The trade works if the market continues to reward predictable margin conversion over headline growth.
• For event-driven accounts, consider a tactical long only on a 5-7% post-earnings fade, with a tight stop below the pre-guidance breakout level. The setup is attractive only if the stock fully prices in the raised full-year numbers; otherwise upside can be 10-15% on backlog confidence.
• Monitor for evidence of mix normalization in the next quarter: if Public Preparedness margins stabilize while Travel Health remains resilient, the stock can re-rate higher over 3-6 months; if not, the upgraded guidance becomes a ceiling rather than a floor.